Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05481658 · ClinicalTrials.gov registry record · Phase 1
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
A Phase 1 study of Cutaneous Metastases, sponsored by Nicholas Gulati.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05481658 is a Phase 1 study of Cutaneous Metastases that is actively recruiting participants, run by Nicholas Gulati. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05481658, a Phase 1 study of Cutaneous Metastases, is actively recruiting participants, sponsored by Nicholas Gulati.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.
Conditions Studied
Interventions
- DRUG Diphencyprone (DPCP)
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05481658
The ClinicalTrials.gov registry entry for NCT05481658 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicholas Gulati, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Metastases appearing as the primary indexed condition, and to 1 intervention - of which Diphencyprone (DPCP) is the first listed.
NCT05481658 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05481658 about?
NCT05481658 is a clinical study titled "Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases". This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compar...
What is the current status of trial NCT05481658?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2022-10-06. Estimated completion is 2030-12.
What conditions does trial NCT05481658 study?
This clinical trial studies the following conditions: Cutaneous Metastases.
What interventions are being tested in trial NCT05481658?
The interventions under investigation include: Diphencyprone (DPCP) (DRUG).
Who is sponsoring clinical trial NCT05481658?
This trial is sponsored by Nicholas Gulati, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05481658 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.